• D-Wave’s new go-to-market (“GTM”) growth strategy, initially focused on key verticals, including logistics, manufacturing, and government, is expected to accelerate the adoption and deployment of commercial quantum technologies
• The GTM approach reinforces the value of the company’s unique annealing quantum computing solutions, which help organizations solve highly complex computational problems today
• According to Hyperion Research, over 80% of enterprises are expected to increase their investments in quantum computing over the next two to three years, with logistics and supply chain management identified as top sectors to benefit from quantum computing capabilities

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently launched a new go-to-market (“GTM”) growth strategy to accelerate the adoption and deployment of commercial quantum technologies. The GTM move extends D-Wave’s position in commercial quantum computing and is initially focused on key verticals, including logistics, manufacturing, and government. The strategy reinforces how the company’s unique annealing quantum computing solutions can help organizations solve complex computational problems today (https://ibn.fm/blzr2).

According to a Hyperion Research report, commissioned by D-Wave, (https://ibn.fm/iOLGW), more than 80% of enterprises surveyed expect to increase their investments in quantum computing over the next two to three years, with logistics and supply chain management identified as top sectors to benefit from quantum computing capabilities. The new GTM strategy sharpens the company’s focus to drive revenue and help customers incorporate D-Wave’s technologies more rapidly into their IT infrastructures. It comes at a time when D-Wave is focused on transitioning customers from experimentation to operational use of quantum.

In support of the company’s vertical strategy for the GTM initiative, D-Wave recently launched a logistics-focused campaign, introducing new resources and highlighting subject matter expertise on how annealing quantum computing is uniquely suited to solve critical logistics challenges. Elements of this campaign include:

• A new ebook (https://ibn.fm/rpXRM): “Moving Forward: How Quantum-Powered Logistics Management is Changing the Game”
• A LinkedIn Live session, which took place on March 7, 2024 with Murray Thom, vice president of quantum technology evangelism at D-Wave, focused on optimization solutions for logistics (https://ibn.fm/OHzLh)
• An upcoming logistics-focused webinar on March 26, 2024, featuring Tecnalia, a technological development center, showcasing how they use quantum hybrid technologies to reduce storage costs and improve vehicle space allocation in their truck-loading application (https://ibn.fm/MfGnN)

“Our new GTM strategy positions us to better serve a market that is ready to reap the tangible benefits of today’s quantum computing solutions,” said Irwan Owen, VP of growth at D-Wave. “We expect this strategic focus will expand our reach and deliver greater value for our customers and shareholders as we help businesses solve today’s real-world optimization challenges.”

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 companies use D-Wave technologies. The company boasts an extensive IP portfolio featuring over 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

The company also recently announced its involvement in the upcoming 36th Annual Roth Conference, to be held March 17-19, where CEO Dr. Alan Baratz and CFO John Markovich will participate. The conference will be held at the Ritz Carlton, Laguna Niguel in Dana Point, California. Dr. Baratz will also participate in a fireside chat, which will be webcast live and archived for future viewing.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding expected growth in investment in quantum computing; the potential impact and expected results of D-Wave’s new GTM strategy; D-Wave’s participation in the 36th Annual Roth Conference; and its planned activities at the conference. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including  the risk that the conference is rescheduled or cancelled; unforeseen changes to travel plans or budgets; general economic conditions and other risks; the company’s ability to expand the company’s customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute the company’s business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; the risk that the company’s restatement of certain previously issued audited and unaudited financial statements or material weaknesses in internal controls could negatively affect investor confidence and raise reputational issues; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose
• With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD
• The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks
• This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated with diabetes. This 8-week study resulted in a 7% reduction in weight, as well as a 19.9% reduction in blood glucose, aligning with other study works in animals that pointed to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes (https://ibn.fm/1XpLx).

With the success of this study, Lexaria looks to kick off its WEIGHT-A24-1 animal study that will seek to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol alone and in combination. This study will be executed by a Health Canada-licensed Canadian research laboratory and is set to commence within 45 days (https://ibn.fm/wrpAD).

This study will comprise 12 arms, 8 of which composition manufacturing has already been completed. Each arm is expected to be dosed for twelve weeks following an acclimation period, during which over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purposes of detailed pharmacokinetic drug delivery analyses. The remaining study arms, 9 through 12, will kick off later due to some information outputs required from the other study arms.

With WEIGHT-A24-1, Lexaria looks to build on the success of its previous studies, including the goal of evidencing DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue. Industry studies have evidenced that small peptide GLP-1R agonists activate a subset of GLP-1R-expressing neurons in the arcuate nucleus involved in weight loss (https://ibn.fm/h1yrv). Having expressed its resolve to focus on GLP-1 studies for the 2024 calendar year, the WEIGHT-A24-1 study is one of several planned for 2024.

It highlights the company’s commitment to its course and creating shareholder value. It also reflects its commitment to further developing its DehydraTECH technology and opening it up to more areas of application that offer value to individuals and companies alike. As Lexaria looks to embark on three human studies this year, including a 12-week chronic dosing human study as well as long-term stability testing, WEIGHT-A24-1 will play an integral role in shaping their outcome and affirming the overall effectiveness of its DehydraTECH technology.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Life EV Group in December 2023 announced its acquisition of a 40% interest in LEV Manufacturing through a share exchange
• LEV Manufacturing Inc. in July 2023 acquired Serial 1 Cycle Company, an e-bike maker founded by Harley-Davidson
• In February 2022, the company announced a name change to Life Electric Vehicles Holdings Inc.
• In November 2021, Second Street Capital Inc. merged with Life Electric Vehicles Holdings Inc.

Life Electric Vehicles Holdings (OTC: LFEV) (d/b/a Life EV Group), along with its subsidiaries, is a developer, manufacturer and distributor in the light electric vehicle industry. The company’s business model focuses on the launch, acquisition and consolidation of multiple brands of e-bikes, e-trikes, e-scooters and light EVs with the aim of positioning itself as an industry leader for the American micro-mobility market.

The light electric vehicle industry, mainly e-bikes, is fast becoming a leading form of EV sales in the U.S. and Europe. In addition to offering ready-to-ride electric vehicles, Life EV Group intends to distribute individual components, including motors, batteries, chargers, controllers and EV parts, to third party manufacturers in both the U.S. and worldwide.

The company’s first acquisition was completed in 2023 with a 40% equity stake in LEV Manufacturing Inc., a related company and American manufacturer of e-bikes. LEV Manufacturing’s assembly utilizes free-trade zone processes with a U.S. Certificate of Origin, eliminating middle layer costs and resulting in cost-effective production and lower MSRPs.

LEV Manufacturing recently completed the acquisition of Serial 1 Cycle Company LLC. Serial 1 is an e-bike maker founded by U.S. motorcycle manufacturer Harley-Davidson in 2018 and spun off as an independent brand in 2020. The acquisition positions Serial 1 for even greater success and long-term growth.

Life EV Group is headquartered in Deerfield Beach, Florida.

Market Opportunity

An analysis from Mordor Intelligence, a market research and advisory firm, estimates the e-bike market to be worth $34.98 billion in 2024 and projects it will expand to reach a value of $51.78 billion by 2029, representing a CAGR of 8.16% during the forecast period.

Mordor attributes forecast market growth primarily to the increasing adoption of electric bikes as a mode of daily transportation around the world. The market is seeing an upsurge in unit sales based on their attractive consumer characteristics, including health benefits, affordability and convenience.

The North American electric bike market is growing as the preference for low-speed two- and three-wheelers has increased in recent years. Various bike-sharing operators are including electric bikes in their fleets, which is expected to support the sales growth of these bikes in the near future.

Management Team

Robert Provost is the CEO of Life EV Group. He was Founder and CEO of Prodeco Technologies, a maker of e-bikes and e-bike parts and accessories. He also serves as President and CEO of LEV Manufacturing Inc. He is Chairman of the board for Serial 1 Cycle Company.

Daniel Del Aguila is COO at Life EV Group. He co-founded Prodeco Technologies and serves as COO of LEV Manufacturing Inc.

Ivan Drusc is CFO at Life EV Group. He is a seasoned accounting and finance professional with a proven track record in industries from insurance to IT and property management. He has served as a key player in businesses ranging in size from startups to publicly traded global companies. He has experience in cost reduction, risk mitigation, IT and ERP systems, outsourcing and restructuring. He is a graduate of the University of Akron with a bachelor’s degree in accounting.

For more information, visit the company’s website at www.LifeElectricVehicles.com.

NOTE TO INVESTORS: The latest news and updates relating to LFEV are available in the company’s newsroom at https://ibn.fm/LFEV

• The global electric boats market is forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030
• Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time
• The company’s new chief financial officer brings invaluable expertise and insight in manufacturing, production and delivery

As the electric boat sector is projected to double in value in the next few years, companies operating in the industry are positioning themselves to meet — and even exceed — the expectations this growth could create. For example, Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating market, has made two key announcements recently: the company unveiled its Phantom vessel, a new rotomolded, recyclable, and hard-to-damage boat (https://ibn.fm/n0Ytr), and it named an industry veteran as it transitions to the manufacturing and delivery phase (https://ibn.fm/O8OPk).

The global electric boats market is on the cusp of significant growth, with the market forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030, reported ResearchandMarket.com (https://ibn.fm/0dMHk). “This remarkable expansion is set to soar at a compound annual growth rate (“CAGR”) of 13.0% from 2023 to 2030,” the report stated. “The driving force behind this surge is the escalating demand for advanced electrical systems in electric boats.

“The electric boats market is poised for transformation, driven by the increasing demand for sustainable transportation solutions, mounting environmental concerns and the evolution of electric propulsion technologies,” the report continued. “Electric boats, also referred to as e-boats or electrically powered vessels, replace traditional internal combustion engines with electric motors and batteries, delivering advantages in terms of efficiency, emissions reduction and operational cost savings.”

With that forecast in mind, Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time. The company debuted the boat at the Miami International Boat Show 2024. The new vessel offers significant market advantages through its economic and environmental benefits. The company noted that the boat, which can comfortably seat up to 10 passengers, is engineered for efficiency. In addition, VMAR has the capacity to produce an estimated 300 units annually, with the potential to scale up to 1,500 units a year, at a cost that is 70% lower than that of fiberglass alternatives.

“We recognize a growing demand for rotomolded boats among our Florida clientele for several reasons,” said Roger Moore, the CEO of Nautical Ventures Marine Group, which has inked an exclusive distribution deal with VMAR. The Phantom’s affordability “enables entry-level ownership; they support both electric and gas motors, appealing to ecoconscious and traditional boaters alike; and their versatility makes the Phantom ideal for various activities, from fishing to leisure. With its 10-person capacity and maintenance-free design, the Phantom meets a wide range of needs.”

As Vision Marine gears up to meet industry demand for the new boat, the company’s new chief financial officer will bring invaluable expertise and insight. The company recently named Raffi Sossoyan as its new CFO, noting that the “strategic appointment marks a significant step as Vision Marine gears up for an ambitious phase focused on manufacturing, production, and delivery, underlining the company’s dedication to scaling its operations and enhancing its market footprint.”

Sossoyan has more than 25 years of experience in global financial and operational leadership. Most recently, he served as vice president of corporate treasury at Velan Inc., a Canadian multinational company. While there, Sossoyan managed financial operations amid global sales exceeding $370 million. Prior to that, as CFO at Valtech Fabrication Inc., he oversaw worldwide sales that totaled more than $50 million.

“Raffi’s robust experience in finance and operations within publicly listed companies, particularly his success at a TSX-listed entity, aligns perfectly with our strategic objectives as we escalate our manufacturing and delivery initiatives,” said CEO Alex Mongeon. “His leadership will be instrumental in fortifying Vision Marine’s financial strategies during this critical phase of our expansion.”

These two recent announcements underscore the Vision Marine Technologies commitment to leading the shift toward electric propulsion in the marine industry, fostering sustainability and achieving superior performance through its innovative E-Motion(TM) technology.

For more information, visit the company’s website at www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Correlate Energy, a publicly traded distributed energy solutions company, has positioned itself as the go-to company given the federal government’s push for greener buildings
• The government’s proposed definition of zero operating emissions buildings, seeks consistency with a framework for long-term goal-setting
• Correlate understands these changing tides and, through its three-pronged strategy, offers building owners and management the most technologically efficient and cost-effective ways to go green

Correlate Energy (OTCQB: CIPI), a publicly traded company positioned to capitalize on America’s move toward efficient energy sourcing and use, is aware of the growing pressure for buildings to become more energy efficient. This follows the federal government’s aggressive push for greener structures and its proposed definition geared toward increasing standardization, consistency, transparency, and accountability.

According to federal definitions, a zero operating emissions building is “Highly energy efficient, free of on-site emissions from energy use, and powered solely by clean energy sources.” The objective of this definition is to achieve consistency and lay down a framework for long-term goal setting. It leverages a building’s energy use as a foundation, offering incentives for existing building owners to improve their overall energy efficiency while providing a roadmap for new buildings to achieve energy efficiency upon construction (https://ibn.fm/aZIAW).

Correlate already recognizes that the energy grid in the U.S. is insufficient for the booming clean energy trend. In addition, it acknowledges that the current infrastructure poses a limit to green energy distribution. Still, it remains committed to helping buildings achieve net zero operating emissions, mainly by constructing the needed infrastructure to address this demand imbalance, while offering four main benefits with its offering. These include real cost savings, project investment funding, consistent long-term incentives, and robust customer demand.

Through its strategy of selling, retaining, and acquiring, Correlate has managed to carve out a significant market share. It is positioning itself as the all-in-one brand for total clean energy solutions, especially as the conversation around zero emissions buildings continues to proliferate and more stringent regulations are enforced.

This market positioning has seen various companies in the U.S. procure its products and services. Recently the company commissioned one of Illinois’ latest rooftop solar facilities for Continental Envelope’s manufacturing plant. This project is set to supply approximately 20-25% of the facility’s overall energy requirements (https://ibn.fm/mUav7). It has now also completed a solar project at American Tire Distributors headquarters in Huntersville, North Carolina. This project is expected to economically reduce CO2 emissions by 5,463 tons over the next two decades, helping the company reduce its carbon footprint (https://ibn.fm/jn0hz).

As the federal government continues its push for net zero emissions buildings, Correlate anticipates a growth in the demand for its products and services. In 2023, over $1.7 trillion was estimated to be invested in technologies such as solar and wind power, electric vehicles, and batteries, making it the most ever spent on clean energy in a single year. It is projected that 2024 might surpass that figure, and Correlate is positioning itself to ride the wave. With its tried and tested solutions, the company has already asserted itself as the go-to brand for decentralized energy generation.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• SenesTech, a rapidly growing company specializing in highly effective fertility control solutions for animal pests, recently announced multiple product distribution deals outside the U.S.
• In Europe, it entered into an agreement with Q-chem, a pest control product supplier in The Netherlands
• In Australia, SenesTech entered into an agreement with Evicom, an environmental management firm with distribution in the country, as well as in New Zealand and the surrounding region
• In Asia, the company partnered with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore

SenesTech (NASDAQ: SNES), a rodent fertility control solutions provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce multiple distribution deals globally in what marks a huge milestone for the company, just two months into the new year. These deals bring YTD 2024 total revenue up more than 80% compared to YTD 2023 (https://ibn.fm/D9icH).

SenesTech also announced its foray into the European market with its distribution agreement with Q-chem, a pest control product supplier in the Netherlands. The move looks to tap into the growing demand for pest control products and services since the country first implemented an Integrated Pest Control (“IPM”) program four years ago with the explicit goal of reducing the reliance on anti-coagulant rodenticides. With its Evolve product, SenesTech is confident that it will dominate this market and become a leader in controlling rats with fertility control.

“Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” noted Mr. Fruendt (https://ibn.fm/6VwGH).

SenesTech is following the country’s requisite regulatory procedure with Q-chem’s help. The process is expected to progress quickly, after which the product will be introduced in Europe.

New Zealand and Australia have also been prime potential markets for SenesTech. Its distribution agreement with Evicom, an environmental management firm based in Australia with distribution throughout Australia, New Zealand, and the surrounding region, opens the company to these two lucrative markets.

“Evicom is thrilled to be appointed exclusive distributors of Evolve for Australia and New Zealand,” noted Simon de Bono, Evicom’s Managing Director.

“Knowing SenesTech really cares about humanely managing animal populations through innovative fertility control aligns with our business strategy,” he added (https://ibn.fm/0nLNe).

SenesTech also announced a distribution agreement with Agro Technic PTE Ltd, a Singapore pest control product manufacturer and distributor. This agreement will cover both a substantial initial stocking order and annual minimums. It will open SenesTech up to Singapore and surrounding regions, expanding its market reach and the potential number of customers it could acquire.

“Agro Technic has been at the forefront of bringing in innovative solutions for the public health sector since the 1970s. We continue to do so year on year, bringing to market solutions that are not only environmentally friendly but, most importantly, effective!” noted Heng Yiwei, Agro Technic’s Managing Director.

“The product range that SenesTech offers, is a perfect fit to our business model, long-term strategy, and market positioning and runs in tandem with the requirements of our garden city,” he added (https://ibn.fm/l2puL).

SenesTech’s management is optimistic that these distribution agreements, coupled with its superior, tried and tested Evolve product, will set the company up for even more success this year, even as it continues to explore new growth opportunities.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

Directors, managers, VPs, regulatory affairs personnel, and service providers of the logistics and operations verticals for the biopharma supply chain across Europe and North America are invited to attend the 3rd BioPharma Supply Chain & Logistics Nexus Conference being held April 25-26, 2024, at the Basel Mariott Hotel, Switzerland. The event aims to address critical issues and challenges in the supply chain and logistics within the biopharmaceutical industry.

The event is hosted by BioPharma Nexus, a premier company organizing prestigious conferences aiming to foster networking and business ties between pharmaceutical and biotech companies and their service providers. The focus lies in building robust relations such that the best healthcare services are available to patients worldwide. Service providers, managers, and company heads can identify and connect with partners to foster important scientific and healthcare collaborations.

Benefits of attending the conference:

• Establishing networking and business relations among powerful industry leaders.
• Gain insightful knowledge and learn about the latest trends in the biopharma spectrum.
• Connect with the industry leaders to stay updated with the latest technological advancements as well as the target audience.
• Learn the latest offerings and get innovative ideas and solutions for business operations.
• Showcase your product and business solutions on a unified conference platform.

The 3rd BioPharma Nexus Conference brings together global leaders and experts on the biopharma supply chain to provide invaluable insights. They will explore topics ranging from improving the supply chain transparency and sustainability in temperature-controlled logistics to novel technologies and trends in the pharmaceutical supply chain. Special attention will be given to the issues and opportunities faced by Contract Manufacturing Organizations (CMOs/CDMOs). New entities can leverage the nexus forum to gain visibility and network with key industry stalwarts.

To know more, please visit https://ibn.fm/nPR98

• CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
• Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
• The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
• The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
• Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://ibn.fm/huSZ8).

A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse commercial leadership roles in the U.S. and globally, spanning sales, marketing, and market access where she has been part of teams that commercialized and launched drugs in various therapeutic areas, from oncology and neurology to immunology.

In her current role as the Chief Commercial Officer of Roivant Sciences (NASDAQ: ROIV), a publicly traded biopharmaceutical company with a $9 billion market cap, Ms. Mahery is playing a vital role in facilitating Roivant’s transformation from a clinical development-focused company to an end-to-end biotech leader. She has worked to establish the company’s commercial operations and capabilities, efforts that have seen Roivant achieve profitable growth across its entire portfolio of over 10 affiliate companies called Vants. Ms. Mahery provides direct commercial leadership to the Vants during the start-up phase. Prior to taking up this role, she held multiple leadership roles at EMD Serono, Inc., a healthcare subsidiary of Merck KGaA.

“We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight, and vast pharma industry network will truly be invaluable,” conveyed Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy’s extensive experience and commercial leadership to assist in positioning the company for success.”

A strong supporter of innovation that brings value to patients, organizations, and society, Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (“GBM”) treatment, saying, “I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team.”

Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.

CNS Pharmaceuticals is currently undertaking a potentially pivotal study of Berubicin for the treatment of GBM. The company completed in January the planned enrollment of 247 participants across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland (https://ibn.fm/dPOwp). The company remains hopeful in its efforts to address GBM and intends to take advantage of the extensive expertise of Ms. Mahery and other members of its capable team to drive success.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Many Landlords across the United States currently face several obstacles in leasing commercial properties to cannabis-focused tenants, on the basis of ongoing federal restrictions that impact real estate factors such as insurance, financing, and permitting
• Zoned Properties has sought to bridge this supply gap, with a portfolio of investment properties seeking to address the needs of the regulated cannabis industry
• The company has recently announced plans to refocus its investment portfolio towards direct-to-consumer retail properties, simultaneously revealing their intentions to market one of their cultivation-oriented sites for sale
• Zoned Properties recently revealed that 3Q2023 revenues had risen by 17.2% YoY, whilst guiding for estimated full year rental revenues of $2.5 million over the course of 2024

In 2021, New York state officially legalized the usage of marijuana for recreational purposes; nevertheless, and nearly three years on from the landmark decision, cannabis supply for retail consumers remains painfully constrained. In April 2023, plans to build out a recreational cannabis dispensary in Harlem’s 125th street was thwarted by a lawsuit filed by a prominent Harlem business group, alleging that the planned dispensary would contribute to social issues in the neighborhood (https://ibn.fm/cB54T).

Despite cannabis being legal in 38 of 50 states for medical use and 24 states for recreational use, cannabis linked businesses are still faced with significant obstacles when looking to secure commercial properties for the cultivation or sale of marijuana-based products. With cannabis still illegal under federal law, commercial landlords seeking to rent out a mortgaged property face the risk of being called on a loan if a property is used for ‘illegal activity’; similarly, landlords open to leasing to cannabis tenants could face constraints in the form of city-specific zoning rules (https://ibn.fm/4XEBB). It is this unique conundrum which Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, is seeking to address.

The United States’ cannabis industry is expected to benefit from a remarkable 13.93% CAGR from 2024 to 2028, resulting in an annual market size of $67.15 billion by the end of 2028. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is seeking to capitalize on the industry’s burgeoning future by targeting commercial properties which have the potential to be acquired and rezoned or permitted for specific purposes, including the regulated and legalized cannabis industry. Separately and in addition to its core real estate development business, the company has sought to leverage upon their considerable commercial real estate expertise within their brokerage business in recent years; since 2021, Zoned Properties Brokerage has closed upwards of $80 million in commercial real estate deals nationally for clients.

Zoned Properties maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses. The company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company leases two properties which are operated as regulated cannabis cultivation and processing facilities. Nonetheless, the company has recently sought to refocus its investment portfolio towards direct-to-consumer properties located in states boasting both, a regulated and legal domestic cannabis industry and robust underlying cannabis consumer demand; in doing so, Zoned Properties has announced that it now considers its cultivation sites as legacy properties, reserving the optionality to potentially sell or leverage these holdings to unlock equity to be deployed towards its core business.

Considering its reaffirmed commercial priorities, Zoned Properties recently revealed that the company has listed its cultivation property located in Chino Hills, Arizona for sale at a purchase price of $16 million. A valuable yet non-core asset within the company’s portfolio, the sale of the Chino Valley property could help further streamline Zoned Properties’ portfolio and help recalibrate its real estate offering towards more direct-to-consumer focused properties (https://ibn.fm/WWgDm).

“As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy, represents a significant capital reallocation opportunity for Zoned Properties. We expect that, if and when the Chino Valley Property is sold, the non-dilutive proceeds from the sale would be instrumental in supporting the company’s future real estate portfolio acquisition plans,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

• Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study
• John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension
• With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive
• This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows the company’s Investigational New Drug (“IND”) application earlier in the year.

The HYPER-H23-1 clinical trial, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will seek to explore the overall effectiveness of its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension. The primary objective will be to evaluate the safety and tolerability in hypertensive patients, with secondary objectives including efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing (https://ibn.fm/ch6DA).

According to John Docherty, President of Lexaria, this clearance by the FDA demonstrates its technology’s overall potential, having met the FDA’s high level of regulatory scrutiny.

“This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization,” noted Mr. Docherty.

Since 2018, Lexaria has conducted five human clinical studies for its DehydraTECH-CBD on 134 healthy, normal, and hypertensive volunteers. The results have been overwhelmingly positive, evidencing reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also produced zero serious adverse events, pointing to DehydraTECH’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

With HYPER-H23-1, Lexaria looks to build on the success of its previous studies, ultimately asserting the superiority of its technology, while also inching closer to tapping into the hypertension treatment market, which was valued at $31.76 billion in 2022, and is expected to reach $43.18 billion by 2030 (https://ibn.fm/Uror5).

“We look forward to commencing this important clinical trial and building upon the wealth of early-stage clinical data we have gathered and presented to the FDA to date demonstrating the safety, efficacy, and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients,” noted Mr. Docherty.

This is a huge milestone for Lexaria and its team, especially following the plans to commence with its diabetes and weight loss animal study, coupled with doubling down on its GLP-1 clinical studies for the 2024 calendar year. All these steps reflect the company’s commitment to creating shareholder value and further developing its DehydraTECH technology, which has the potential to be a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX